Rare‑Disease Biotechs Push Back on Trump’s Price‑Cut Push While PBMs Slip Around State Laws

When you’re a biotech company that spends years hunting for a drug that helps, say, three hundred patients nationwide, a top‑down price‑cut directive feels a lot like a slap in the face. That’s the feeling echoing through the halls of rare‑disease firms right now, as they scramble to convince the Trump administration to carve out a special exemption for their ultra‑niche therapies.

It isn’t just a matter of pride or principle; it’s economics 101. The new pilot, announced earlier this year, would force participating manufacturers to shave a set percentage off the list price of drugs that qualify as “high‑cost.” For a molecule that already costs $600,000 a year, a 15 % cut translates into a $90,000 revenue hit per patient – a hit that can make the difference between staying afloat and going under.

So you’ll find these companies marching, politely but firmly, into the White House, meeting with officials from HHS and the Office of Management and Budget. Their pitch is a blend of data, anecdotes, and a dash of emotion: “We’re saving lives that would otherwise be lost,” they say, “but the math just doesn’t work if you bulldoze our pricing model.” The lobbyists hand over glossy decks, citing the tiny patient pools, the high cost of gene‑editing platforms, and the fact that many of these therapies are still under patent protection.

It’s not just a one‑sided conversation. Republicans in Congress, still nursing the memory of the last administration’s push to rein in drug costs, are watching closely. A recent KFF poll shows voters rank rising out‑of‑pocket costs as their top health concern, while GOP lawmakers are equally vocal about curbing fraud in Medicare and Medicaid. That dual focus creates a political sweet spot where both sides claim to care about affordability, yet their definitions of “affordable” diverge sharply.

Meanwhile, a parallel drama is unfolding in the background – one that involves the pharmacy‑benefit managers (PBMs) who sit between drugmakers, insurers, and patients. In the wake of a wave of state‑level price‑transparency statutes, PBMs have begun to lean on multi‑state licensing agreements, effectively ping‑ponging claims across state lines to avoid triggering the new reporting thresholds.

It’s a bit of legal gymnastics, really. By classifying certain transactions as “out‑of‑state” services, PBMs can sidestep the very statutes that were meant to shine a light on outrageous pricing. Critics argue this is a clever loophole that undermines the spirit of the laws, while PBMs counter that they’re simply operating within the bounds of existing commerce regulations.

The result is a tangled web where rare‑disease drugmakers seek relief from a federal price‑cut pilot, and PBMs quietly find ways to duck state‑level transparency rules. Patients caught in the middle often hear the same refrain: “We’re doing everything we can, but the system is a mess.”

What comes next? Probably more lobbying, a few more press releases, and perhaps a new round of congressional hearings where both sides will argue that they’re protecting patients – just in very different ways. One thing’s for sure: the debate over how to balance innovation, access, and cost is far from over.